Related Experiment Video
Updated: Sep 24, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Targeting XPO1-Dependent Nuclear Export in Cancer
Ekaterina Kim1, Daria A Mordovkina2, Alexey Sorokin3
1The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ekim3@mdanderson.org.
Abstract:
Nucleocytoplasmic transport of macromolecules is tightly regulated in eukaryotic cells. XPO1 is a transport factor responsible for the nuclear export of several hundred protein and RNA substrates. Elevated levels of XPO1 and recurrent mutations have been reported in multiple cancers and linked to advanced disease stage and poor survival. In recent years, several novel small-molecule inhibitors of XPO1 were developed and extensively tested in preclinical cancer models and eventually in clinical trials. In this brief review, we summarize the functions of XPO1, its role in cancer, and the latest results of clinical trials of XPO1 inhibitors.
Insights
Exportin 1 (XPO1) protein export is crucial for cells. Inhibiting XPO1 shows promise in treating various cancers, with ongoing clinical trials evaluating its effectiveness.
Area of Science:
- Cell biology
- Molecular biology
- Oncology
Background:
- Nucleocytoplasmic transport is vital for eukaryotic cells.
- Exportin 1 (XPO1) mediates the export of numerous proteins and RNAs.
- Increased XPO1 levels and mutations are linked to cancer progression and poor prognosis.
Purpose of the Study:
- To review the functions of XPO1.
- To discuss the role of XPO1 in cancer development.
- To summarize recent clinical trial outcomes for XPO1 inhibitors.
Main Methods:
- Literature review of XPO1 functions.
- Analysis of XPO1's role in oncogenesis.
- Summary of preclinical and clinical data for XPO1 inhibitors.
Main Results:
- XPO1 is essential for exporting key cellular components.
- Dysregulation of XPO1 is implicated in multiple cancer types.
- Novel small-molecule XPO1 inhibitors have shown efficacy in preclinical and clinical studies.
Conclusions:
- XPO1 is a significant factor in cancer biology.
- Targeting XPO1 with inhibitors represents a promising therapeutic strategy.
- Ongoing clinical trials are evaluating the potential of XPO1 inhibitors in cancer treatment.
Related Concept Videos
Nuclear Export
NES are of three types- the canonical 10-residue long leucine-rich signal and other...
Nuclear Export of mRNA
Nuclear Protein Sorting
Proteins targeted to the nucleus carry nuclear localization signals or NLS recognized by import receptors in the cytosol. Similarly, proteins with nuclear export signals are recognized by export receptors. Import and export receptors are...
Regulation of Nuclear Protein Sorting
Directionality of Nuclear Transport
Targeted Cancer Therapies
There are several types of targeted therapies against...

